|
Variables
|
Radiotherapy
Alone
N=35 (62.5%) |
Sequential Chemotherapy and radiotherapy
N=21 (37.5%) |
P value |
Comorbids
(DM/HTN)
Yes
No |
18 (51.5%)
17 (48.5%)
|
11 (52.4%)
10 (47.6%) |
0.9 |
FIGO Stage
IA
IB
IIA
IIB |
2 (5.7%)
16 (45.7%)
9 (25.8%)
8 (22.8%) |
-
9 (43.0%)
6 (28.5%)
6 (28.5%)
|
0.6 |
Cell Type
Endometroid
Serous papillary
Clear cell
|
33 (94.2%)
1 (2.9%)
1 (2.9%) |
19 (90.5%)
2 (9.50%)
- |
0.8 |
Pathological grade
G1
G2
G3 |
5 (14.2%)
12 (34.3%)
18 (51.5%) |
4 (19.0%)
8 (38.0%)
9 (43.0%) |
0.9 |
LVI
Yes
No |
12 (34.3%)
23 (65.7%) |
6 (28.5%)
15 (71.5%) |
0.7 |
ER/ PR Receptors
Positive
Negative
unknown |
6 (17.1%)
7 (20.0 %%)
22 (62.9%) |
2 (9.5%)
4 (19.0%)
15 (71.5%) |
0.8 |
LN
Positive
Negative |
3 (8.6%)
32 (91.4%) |
1 (4.8%)
20 (95.2%) |
0.8 |
Squamous Metaplasia
Yes
No |
3 (8.6%)
32 (91.4%) |
1 (4.8%)
20 (95.2%) |
0.9 |
Dose RT
45 Gy EBRT + VBT 15 Gy
50.4 Gy EBRT+ VBT 15 Gy |
23 (65.7%)
12 (34.3%) |
11 (52.4%)
10 (47.6%) |
0.8 |
